Full Picture

Extension usage examples:

Here's how our browser extension sees the article:
Appears moderately imbalanced

Article summary:

1. Dupilumab, a human antibody that blocks signaling of interleukin-4/-13, key drivers of type 2 inflammation, reduced severe asthma exacerbations and improved lung function in children aged 6-11 years with uncontrolled, moderate-to-severe asthma.

2. Weight-tiered dose regimens achieved mean concentrations within the dupilumab therapeutic range and median decreases in type 2 biomarker levels were similar between dose regimens.

3. Reductions in type 2 biomarkers were greater in patients treated with dupilumab compared to placebo, with median percent changes from baseline at Week 52 for serum total IgE, TARC, blood eosinophils, and FeNO.

Article analysis: